Back to top
more

IntraCellular Therapies (ITCI)

(Real Time Quote from BATS)

$54.19 USD

54.19
248,074

+0.74 (1.38%)

Updated Dec 2, 2022 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.51%
2Buy17.96%
3Hold9.47%
4Sell5.16%
5Strong Sell2.21%
S&P50010.66%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Biomedical and Genetics

Trades from $1

Balance Sheet

Research for ITCI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for IntraCellular Therapies Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Assets          
Cash & Equivalents 414 659 224 348 464
Receivables 20 11 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 8 7 0 0 0
Other Current Assets 25 14 6 8 5
Total Current Assets 467 691 230 355 469
Net Property & Equipment 2 2 2 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 1 1
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 490 717 251 357 471
Liabilities & Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Notes Payable 0 0 0 0 0
Accounts Payable 9 6 7 14 6
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 38 26 26 22 8
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 53 37 36 36 14
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 3 3
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 72 60 56 39 17
Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,639 1,593 905 881 862
Retained Earnings -1,221 -937 -710 -562 -407
Other Equity 0 0 0 -1 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 418 657 195 318 454
Total Liabilities & Shareholder's Equity 490 717 251 357 471
Total Common Equity 418 657 195 318 454
Shares Outstanding 81.40 80.10 55.40 54.70 54.50
Book Value Per Share 5.13 8.20 3.52 5.81 8.34

Fiscal Year End for IntraCellular Therapies Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2022 6/30/2022 3/31/2022 12/31/2021 9/30/2021
Assets          
Cash & Equivalents 630 679 773 414 479
Receivables 62 47 33 20 17
Notes Receivable 0 0 0 0 0
Inventories 24 25 8 8 8
Other Current Assets 44 38 34 25 29
Total Current Assets 760 789 848 467 533
Net Property & Equipment 2 2 2 2 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 782 812 869 490 557
Liabilities & Shareholders Equity 9/30/2022 6/30/2022 3/31/2022 12/31/2021 9/30/2021
Notes Payable 0 0 0 0 0
Accounts Payable 14 11 12 9 12
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 56 52 40 38 32
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 77 71 59 53 50
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 97 90 76 72 70
Shareholders Equity 9/30/2022 6/30/2022 3/31/2022 12/31/2021 9/30/2021
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,124 2,107 2,089 1,639 1,622
Retained Earnings -1,433 -1,380 -1,293 -1,221 -1,136
Other Equity -6 -5 -3 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 685 722 793 418 487
Total Liabilities & Shareholder's Equity 782 812 869 490 557
Total Common Equity 685 722 793 418 487
Shares Outstanding 94.40 94.30 94.30 81.40 81.30
Book Value Per Share 7.26 7.66 8.41 5.13 5.99